BackAnxo Pharmaceutical , Ltd. Overview

Anxo Pharmaceutical , Ltd. Operating Income

Track Anxo Pharmaceutical , Ltd.'s operating income ($-86M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

-$20.48M
↑ 22.51% YoY

As of Jun 30, 2026

Annual Operating Income (TTM)

-$85.71M
↓ 163.26% YoY

Trailing 12 months ending Jun 30, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Anxo Pharmaceutical , Ltd. (6677.TWO) FAQ

As of the most recent data (June 2026), 6677.TWO shows a operating income of $-86M. That compares with $140M in the prior-year period — down 163.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6677.TWO's operating income is now $-86M (was $140M) — a 163.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Anxo Pharmaceutical , Ltd. is outperforming or lagging.

Tracking 6677.TWO's operating income over time shows whether Anxo Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $-86M That compares with $140M in the prior-year period — down 163.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Anxo Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-86M) with ownership activity and broader fundamentals.